Návrh liečiv (Slovak Wikipedia)

Analysis of information sources in references of the Wikipedia article "Návrh liečiv" in Slovak language version.

refsWebsite

Global rank Slovak rank

16doi.org

2^nd place

7^th place

11worldcat.org

5^th place

1^st place

6elsevier.com

610^th place

631^st place

3nature.com

234^th place

71^st place

1wiley.com

222^nd place

174^th place

1mdpi.com

2,912^th place

1,645^th place

1f1000research.com

low place

1eurekaselect.com

low place

1tandfonline.com

507^th place

468^th place

1sagepub.com

731^st place

948^th place

doi.org

dx.doi.org

TOLLENAERE, J. P.. The role of structure-based ligand design and molecular modelling in drug discovery. Pharmacy World and Science, 1996, roč. 18, čís. 2, s. 56–62. Dostupné online [cit. 2020-01-23]. ISSN 0928-1231. DOI: 10.1007/bf00579706.
TAKENAKA, T.. Classical vs reverse pharmacology in drug discovery. BJU International, 2001, roč. 88, čís. s2, s. 7–10. Dostupné online [cit. 2020-01-23]. ISSN 1464-410X. DOI: 10.1111/j.1464-410X.2001.00112.x. (po anglicky)
DIXON, Scott J; STOCKWELL, Brent R. Identifying druggable disease-modifying gene products. Current Opinion in Chemical Biology, 2009-12, roč. 13, čís. 5-6, s. 549–555. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.cbpa.2009.08.003. (po anglicky)
IMMING, Peter; SINNING, Christian; MEYER, Achim. Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 2006-10-01, roč. 5, čís. 10, s. 821–834. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd2132. (po anglicky)
ANDERSON, Amy C.. The Process of Structure-Based Drug Design. Chemistry & Biology, 2003-09, roč. 10, čís. 9, s. 787–797. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.chembiol.2003.09.002. (po anglicky)
RECANATINI, Maurizio; BOTTEGONI, Giovanni; CAVALLI, Andrea. In silico antitarget screening. Drug Discovery Today: Technologies, 2004-12, roč. 1, čís. 3, s. 209–215. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.ddtec.2004.10.004. (po anglicky)
SCOMPARIN, Anna; POLYAK, Dina; KRIVITSKY, Adva. Achieving successful delivery of oligonucleotides — From physico-chemical characterization to in vivo evaluation. Biotechnology Advances, 2015-11, roč. 33, čís. 6, s. 1294–1309. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.biotechadv.2015.04.008. (po anglicky)
YOUSSEF, Maryam; HITTI, Cynthia; PUPPIN CHAVES FULBER, Julia. Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules, 2023-10-09, roč. 13, čís. 10, s. 1497. Dostupné online [cit. 2024-01-11]. ISSN 2218-273X. DOI: 10.3390/biom13101497. (po anglicky)
SAHIN, Ugur; KARIKÓ, Katalin; TÜRECI, Özlem. mRNA-based therapeutics — developing a new class of drugs. Nature Reviews Drug Discovery, 2014-10, roč. 13, čís. 10, s. 759–780. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd4278. (po anglicky)
SWINNEY, David C.; LEE, Jonathan A.. Recent advances in phenotypic drug discovery. F1000Research, 2020-08-07, roč. 9, s. 944. Dostupné online [cit. 2024-01-11]. ISSN 2046-1402. DOI: 10.12688/f1000research.25813.1. (po anglicky)
MOFFAT, John G.; VINCENT, Fabien; LEE, Jonathan A.. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 2017-08, roč. 16, čís. 8, s. 531–543. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd.2017.111. (po anglicky)
YUAN, Yaxia; PEI, Jianfeng; LAI, Luhua. Binding Site Detection and Druggability Prediction of Protein Targets for Structure- Based Drug Design. Current Pharmaceutical Design, roč. 19, čís. 12, s. 2326–2333. Dostupné online [cit. 2024-01-11]. DOI: 10.2174/1381612811319120019. (po anglicky)
RISHTON, Gilbert M.. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today, 2003-01, roč. 8, čís. 2, s. 86–96. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/S1359644602025722. (po anglicky)
NICOLAOU, Christos A.; BROWN, Nathan. Multi-objective optimization methods in drug design. Drug Discovery Today: Technologies, 2013-09, roč. 10, čís. 3, s. e427–e435. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.ddtec.2013.02.001. (po anglicky)
BAN, Thomas A.. The role of serendipity in drug discovery. Dialogues in Clinical Neuroscience, 2006-09-30, roč. 8, čís. 3, s. 335–344. Dostupné online [cit. 2024-01-11]. ISSN 1958-5969. DOI: 10.31887/DCNS.2006.8.3/tban. (po anglicky)
ETHIRAJ, Sendil K.; LEVINTHAL, Daniel. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly, 2004-09, roč. 49, čís. 3, s. 404–437. Dostupné online [cit. 2024-01-11]. ISSN 0001-8392. DOI: 10.2307/4131441. (po anglicky)

elsevier.com

linkinghub.elsevier.com

DIXON, Scott J; STOCKWELL, Brent R. Identifying druggable disease-modifying gene products. Current Opinion in Chemical Biology, 2009-12, roč. 13, čís. 5-6, s. 549–555. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.cbpa.2009.08.003. (po anglicky)
ANDERSON, Amy C.. The Process of Structure-Based Drug Design. Chemistry & Biology, 2003-09, roč. 10, čís. 9, s. 787–797. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.chembiol.2003.09.002. (po anglicky)
RECANATINI, Maurizio; BOTTEGONI, Giovanni; CAVALLI, Andrea. In silico antitarget screening. Drug Discovery Today: Technologies, 2004-12, roč. 1, čís. 3, s. 209–215. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.ddtec.2004.10.004. (po anglicky)
SCOMPARIN, Anna; POLYAK, Dina; KRIVITSKY, Adva. Achieving successful delivery of oligonucleotides — From physico-chemical characterization to in vivo evaluation. Biotechnology Advances, 2015-11, roč. 33, čís. 6, s. 1294–1309. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.biotechadv.2015.04.008. (po anglicky)
RISHTON, Gilbert M.. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today, 2003-01, roč. 8, čís. 2, s. 86–96. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/S1359644602025722. (po anglicky)
NICOLAOU, Christos A.; BROWN, Nathan. Multi-objective optimization methods in drug design. Drug Discovery Today: Technologies, 2013-09, roč. 10, čís. 3, s. e427–e435. Dostupné online [cit. 2024-01-11]. DOI: 10.1016/j.ddtec.2013.02.001. (po anglicky)

eurekaselect.com

YUAN, Yaxia; PEI, Jianfeng; LAI, Luhua. Binding Site Detection and Druggability Prediction of Protein Targets for Structure- Based Drug Design. Current Pharmaceutical Design, roč. 19, čís. 12, s. 2326–2333. Dostupné online [cit. 2024-01-11]. DOI: 10.2174/1381612811319120019. (po anglicky)

f1000research.com

SWINNEY, David C.; LEE, Jonathan A.. Recent advances in phenotypic drug discovery. F1000Research, 2020-08-07, roč. 9, s. 944. Dostupné online [cit. 2024-01-11]. ISSN 2046-1402. DOI: 10.12688/f1000research.25813.1. (po anglicky)

mdpi.com

YOUSSEF, Maryam; HITTI, Cynthia; PUPPIN CHAVES FULBER, Julia. Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules, 2023-10-09, roč. 13, čís. 10, s. 1497. Dostupné online [cit. 2024-01-11]. ISSN 2218-273X. DOI: 10.3390/biom13101497. (po anglicky)

nature.com

IMMING, Peter; SINNING, Christian; MEYER, Achim. Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 2006-10-01, roč. 5, čís. 10, s. 821–834. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd2132. (po anglicky)
SAHIN, Ugur; KARIKÓ, Katalin; TÜRECI, Özlem. mRNA-based therapeutics — developing a new class of drugs. Nature Reviews Drug Discovery, 2014-10, roč. 13, čís. 10, s. 759–780. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd4278. (po anglicky)
MOFFAT, John G.; VINCENT, Fabien; LEE, Jonathan A.. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 2017-08, roč. 16, čís. 8, s. 531–543. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd.2017.111. (po anglicky)

sagepub.com

journals.sagepub.com

ETHIRAJ, Sendil K.; LEVINTHAL, Daniel. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly, 2004-09, roč. 49, čís. 3, s. 404–437. Dostupné online [cit. 2024-01-11]. ISSN 0001-8392. DOI: 10.2307/4131441. (po anglicky)

tandfonline.com

BAN, Thomas A.. The role of serendipity in drug discovery. Dialogues in Clinical Neuroscience, 2006-09-30, roč. 8, čís. 3, s. 335–344. Dostupné online [cit. 2024-01-11]. ISSN 1958-5969. DOI: 10.31887/DCNS.2006.8.3/tban. (po anglicky)

wiley.com

onlinelibrary.wiley.com

TAKENAKA, T.. Classical vs reverse pharmacology in drug discovery. BJU International, 2001, roč. 88, čís. s2, s. 7–10. Dostupné online [cit. 2020-01-23]. ISSN 1464-410X. DOI: 10.1111/j.1464-410X.2001.00112.x. (po anglicky)

worldcat.org

TOLLENAERE, J. P.. The role of structure-based ligand design and molecular modelling in drug discovery. Pharmacy World and Science, 1996, roč. 18, čís. 2, s. 56–62. Dostupné online [cit. 2020-01-23]. ISSN 0928-1231. DOI: 10.1007/bf00579706.
Drug design : structure- and ligand-based approaches. Cambridge [U.K.] : Cambridge University Press, 2010. Dostupné online. ISBN 978-0-521-88723-6.
BEARZI, MADDALENA.. Beautiful minds : the parallel lives of great apes and dolphins. Cambridge, Mass. : Harvard University Press, 2008. Dostupné online. ISBN 978-0-674-03379-5.
TAKENAKA, T.. Classical vs reverse pharmacology in drug discovery. BJU International, 2001, roč. 88, čís. s2, s. 7–10. Dostupné online [cit. 2020-01-23]. ISSN 1464-410X. DOI: 10.1111/j.1464-410X.2001.00112.x. (po anglicky)
IMMING, Peter; SINNING, Christian; MEYER, Achim. Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 2006-10-01, roč. 5, čís. 10, s. 821–834. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd2132. (po anglicky)
YOUSSEF, Maryam; HITTI, Cynthia; PUPPIN CHAVES FULBER, Julia. Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules, 2023-10-09, roč. 13, čís. 10, s. 1497. Dostupné online [cit. 2024-01-11]. ISSN 2218-273X. DOI: 10.3390/biom13101497. (po anglicky)
SAHIN, Ugur; KARIKÓ, Katalin; TÜRECI, Özlem. mRNA-based therapeutics — developing a new class of drugs. Nature Reviews Drug Discovery, 2014-10, roč. 13, čís. 10, s. 759–780. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd4278. (po anglicky)
SWINNEY, David C.; LEE, Jonathan A.. Recent advances in phenotypic drug discovery. F1000Research, 2020-08-07, roč. 9, s. 944. Dostupné online [cit. 2024-01-11]. ISSN 2046-1402. DOI: 10.12688/f1000research.25813.1. (po anglicky)
MOFFAT, John G.; VINCENT, Fabien; LEE, Jonathan A.. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 2017-08, roč. 16, čís. 8, s. 531–543. Dostupné online [cit. 2024-01-11]. ISSN 1474-1776. DOI: 10.1038/nrd.2017.111. (po anglicky)
BAN, Thomas A.. The role of serendipity in drug discovery. Dialogues in Clinical Neuroscience, 2006-09-30, roč. 8, čís. 3, s. 335–344. Dostupné online [cit. 2024-01-11]. ISSN 1958-5969. DOI: 10.31887/DCNS.2006.8.3/tban. (po anglicky)
ETHIRAJ, Sendil K.; LEVINTHAL, Daniel. Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability. Administrative Science Quarterly, 2004-09, roč. 49, čís. 3, s. 404–437. Dostupné online [cit. 2024-01-11]. ISSN 0001-8392. DOI: 10.2307/4131441. (po anglicky)